Alpha emitters, radiochemistry perspective

With 15+ years of experience spanning alpha- and beta-emitter-based radioligand therapies, Kevin Roland has built and led end-to-end CMC strategies for biologics, peptides, and small-molecule based radiopharmaceuticals, including the design and qualification of GMP facilities, the development of Actinium-225 production and labeling processes, and the orchestration of global CDMO networks.
 

Currently serving as Vice-President of CMC Process Development for Abdera Therapeutics, Kevin Roland brings a execution-focused perspective to the challenges of alpha emitters management, a deep radiochemistry expertise as well as operational and regulatory leadership.
 

Kevin Roland

• Senior CMC and Operations Leader in Radiopharmaceuticals Development
• Vice-President of CMC Process Development, Abdera Therapeutics